Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 201–300 of 1,639
Cleto, A. S., Schirlo, J. M., Beltrame, M. L., Gomes, V. H. O., Acras, I. H., Neiverth, G. S., da Silva, B. B., Juliatto, B. M. S., Machozeki, J., & Martins, C. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01646-9 · Cited by 37
“Therefore, despite this limitation, there was no difference in the result.”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“In these and other trials, patients have reported that the incretin treatment improved their health status as assessed using the Kansas City Cardiomyopathy Questionnaire [44].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Lin, X., Wu, G., Wang, S., & Huang, J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10362-x · Cited by 34
Davies, M. J., van der Meer, P., Verma, S., Patel, S., Chinnakondepalli, K. M., Borlaug, B. A., Butler, J., Kitzman, D. W., Shah, S. J., Harring, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00304-8 · Cited by 32
Self-citationReddy, Y. N. V., Frantz, R. P., Hassoun, P. M., Hemnes, A. R., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.061 · Cited by 30
Self-citationCardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“Over a median follow-up of 15.9 months, oral semaglutide was non-inferior to placebo for MACE (HR 0.79; 95% CI 0.57–1.11; p < 0.001) but did not demonstrate superiority ( p = 0.17) [201].”
InfluentialChiang, C., Song, J., Chi, K., Chang, Y.-C., Xanthavanij, N., Chang, Y., Hsia, Y. P., Chiang, C.-H., Ghamari, A., Reynolds, K. L., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115170 · Cited by 35
Lin, Y., Liao, K., Yu, T., Wu, J., & Lai, C. (2025) · Nature Communications · doi:10.1038/s41467-025-59616-2 · Cited by 42
“Emerging evidence suggests that GLP-1 receptor agonists (GLP-1 RA) may offer clinical bene fi ts in HFpEF patients through anti-in fl ammatory and hemodynamic effects 5,6 .”
Non-canonical G protein signaling
Nürnberg, B., Beer‐Hammer, S., Reisinger, E., & Leiss, V. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108589 · Cited by 30
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Packer, M., Zile, M. R., Desai, A. S., Shah, A. M., Čikeš, M., Merkely, B. P., Gori, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3304 · Cited by 30
Self-citationPharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Cardioprotective Effects of Semaglutide on Isolated Human Ventricular Myocardium
Krammer, T., Baier, M. J., Hegner, P., Zschiedrich, T., Lukas, D., Wolf, M., Phu, C. L., Lutz, V., Evert, K., Kozakov, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3644 · Cited by 33
“Differences in myocardial GLP-1 receptor expression may explain the varying dose–response of Ca transients to semaglutide between the human AS patients with a HFpEF-like phenotype, Our data may provide a rationale for the clinical investigation of high-dose semaglutide in subsets of HF patients and…”
Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“…and HFpEF—with and without diabetes—semaglu-tide 2.4 mg weekly led to a placebo-subtracted weight reduction of 10.7%, reductions in systemic inflammation, and significant improvements in symptoms as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Sum-mary Score (KCCQ-CSS) [66].”
InfluentialSemaglutide and Heart Failure with Preserved Ejection Fraction and Obesity
(2023) · New England Journal of Medicine · doi:10.1056/nejmc2312296 · Cited by 26
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Self-citationYin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 57
Tanaka, A., & Node, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01737-0 · Cited by 29
“More recently, GLP-1RA (semaglutide) therapy proved to be clinically effective for improving the symptoms and physical limitations in patients with heart failure with preserved ejection fraction and obesity [21].”
Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure
Hahn, V. S., Selvaraj, S., Sharma, K., & Shah, S. H. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.04.008 · Cited by 33
Self-citationChiang, C., Song, J., Chang, Y., Osataphan, S. A., Lee, Y.-C., Chang, K.-Y., Chi, K.-Y., Chiang, C., Dua, A., Lake, L. L., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015871 · Cited by 28
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
“In contrast, others find no signifi - cant association [ 9, 10].”
The association between weight loss medications and cardiovascular complications
Başer, O., Samayoa, G., Rodchenko, K., Isenman, L., Baser, E., & Yapar, N. (2024) · Obesity · doi:10.1002/oby.24037 · Cited by 32
“Our study showed a reduction in the incidence of heart failure, which supports the findings of previous studies that have demonstrated AOMs ’ effectiveness in improving health outcomes of patients with heart failure [23].”
ResultKHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.448 · Cited by 25
Self-citationShooshtarian, A. K., O’Gallagher, K., Shah, A. M., & Zhang, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10487-1 · Cited by 34
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
Ni, X., Feng, X., Wang, Z., Zhang, Y., Little, P. J., Cao, Y., Xu, S., Tang, L., & Weng, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01265-0 · Cited by 29
Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine
Tănăsescu, M., Rosu, A.-M., Mincă, A., Rosu, A.-L., Grigorie, M., Timofte, D., & Ionescu, D. (2025) · Diagnostics · doi:10.3390/diagnostics15233025 · Cited by 41
“These cardiometabolic improvements were more pronounced in those with visceral adiposity, supporting the hypothesis that therapies targeting ectopic fat depots such as epicardial adipose tissue may offer pleiotropic benefits in obesity-related HFpEF [49].”
Köseoğlu, F. D., & Özlek, B. (2024) · Diagnostics · doi:10.3390/diagnostics14020209 · Cited by 36
Sarcopenic obesity and weight loss-induced muscle mass loss
Caturano, A., Amaro, A., Berra, C., & Conte, C. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001131 · Cited by 73
Perone, F., Spadafora, L., Pratesi, A., Nicolaio, G., Pala, B., Franco, G., Ruzzolini, M., & Ambrosetti, M. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200331 · Cited by 47
“Recent developments, exemplified by the SELECT [6] and STEP-HFpEF [7] trials in 2023, underscore the utilization of Glucagon-like peptide 1 (GLP-1) receptor agonist antidiabetic drugs within the specific context of obesity.”
BackgroundSagy, Y. W., Lavie, G., Ramot, N., Battat, E., Arbel, R., Reges, O., & Diker, D. (2024) · Nature Medicine · doi:10.1038/s41591-024-03052-0 · Cited by 30
“Notably, improvements in CHF symptoms 10 , reduction in hospitalizations for heart failure 12 , and decreases in cardiovascular and all-cause mortality in patients with cardiovascular disease were reported with GLP-1RA even when only modest weight loss was achieved 14 .”
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“A one-year study with injected semaglutide (2.4 mg once weekly) has noted reduced symptoms (such as fatigue, dyspnoea and oedema) and improved physical capacity in obese patients with heart failure with preserved ejection fraction (STEP-HFpEF) [26].”
BackgroundInfluentialPrecision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF
Rosano, G. M. C., Vitale, C., & Spoletini, I. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0058 · Cited by 31
“In the STEP-HFpEF study, 39) treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss in obese HFpEF patients, than placebo.”
InfluentialPathak, R. K., Elliott, A. D., Lau, D. H., Middeldorp, M. E., Linz, D., Fitzgerald, J. L., Gupta, A. K., Ariyaratnam, J., Malik, V., Noubiap, J. J., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4007 · Cited by 43
Self-citationBonaca, M. P., Catarig, A., Hansen, Y., Houlind, K. C., Ramesh, C. K., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae071 · Cited by 26
Self-citationMalnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
DRIGGIN, E., & GOYAL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.01.005 · Cited by 24
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
“75,76 Tirzepatide is the first medical therapy to improve symptoms of obstructive sleep apnoea in people with and without positive airway pressure treatment, consistent with the degree of weight loss seen ( (cid:1) 18%).”
Multimorbidity in patients with atrial fibrillation
Lobeek, M., Middeldorp, M. E., Gelder, I. C. V., & Rienstra, M. (2024) · Open Heart · doi:10.1136/openhrt-2024-002641 · Cited by 28
“61 62 These medications may influence multimorbidity with their weight-loss effect together with improvement in blood pressure, diabetes control, improved mental health and other cardiovascular conditions, also in patients with AF.”
BackgroundCastañé, H., Jiménez-Franco, A., Hernández‐Aguilera, A., Martínez-Navidad, C., Cambra-Cortés, V., Onoiu, A.-I., Jiménez-Aguilar, J. M., París, M., Hernández, M., Parada, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105532 · Cited by 34
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“…BMI stratum ( < 35 and ≥ 35) revealed a score of 60.1 wins for the semaglutide group and 34.9 wins for the placebo group (stratified WR 1.72; 95% CI 1.37 to 2.15; p < 0.001), with a difference of at least 15 points in the change in KCCQ-CSS contributing the most wins for semaglutide (Table 3) [50].”
BackgroundMethodInfluentialSelf-citationVerma, R., Dhingra, N. K., & Connelly, K. A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001113 · Cited by 24
“Phenotyping HFpEF patients on inflammatory cytokines remains an important area of ongoing research, and unique obese-inflammatory phenotypes have been recently reported [40,41].”
BackgroundKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 56
Elevated C-reactive protein and cardiovascular risk
Chia, J. E., & Ang, S. P. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001215 · Cited by 25
“Studies have shown that semaglutide significantly reduced the baseline CRP levels in those with obesity-related heart failure [39,40].”
Chang, M. G., & Bittner, E. A. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02810-5 · Cited by 26
Fragasso, G., Stolfo, D., Anker, M. S., Bayés‐Genís, A., Chioncel, O. D., Heymans, S. R. B., Jhund, P. S., Lewis, B. S., Lopaschuk, G. D., Lund, L. H., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3703 · Cited by 38
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Nogueira, J. P. (2024) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2024.03.012 · Cited by 22
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
“Both semaglutide and tirzepatide appear to have benefits in composite cardiovascular outcomes within patients with obesity and HFpEF, although the mechanisms are currently unclear [144, 146, 153].”
Naito, A., Kagami, K., Yuasa, N., Harada, T., Sorimachi, H., Murakami, F., Saito, Y., Tani, Y., Kato, T., Wada, N., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3334 · Cited by 25
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
“18 As a result, conflicting results of GLP-1RAs on the effects of reverse cardiac remodelling have been concluded in different trials and meta-analyses.”
ResultAutoimmune Disorders in Heart Failure With Preserved Ejection Fraction
Tada, A., Doi, S., Harada, T., Ibe, T., Naser, J. A., Amdahl, M., Reddy, Y. N. V., & Borlaug, B. A. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2024.04.016 · Cited by 25
Self-citationStone, C. R., Harris, D. D., Broadwin, M., Kanuparthy, M., Nho, J.-W., Yalamanchili, K., Hamze, J., Abid, M. R., & Sellke, F. W. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321850 · Cited by 26
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 24
“Subjects treated with semaglutide experienced a significant decrease from baseline in the KCCQ clinical summary score, a 10.7% body weight reduction, and a 20.3 m improvement in 6 min walk distance, without significant differences in the rate of adverse events [28].”
BackgroundInfluentialGLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 37
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Acevedo, M., Córdova, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 28
Rasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 28
“30,31 Key clinical trials evaluating potential HFpEF therapies commonly use a LVEF eligibility lower cut-off threshold of 40% or 45% ( Figure 3), 32 – 39 thereby also including patients with HFmrEF.”
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Tamargo, J. L., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinándy, P., Grove, E. L., Rocca, B., Magavern, E. F., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae013 · Cited by 27
Quiriarte, H. D., Noland, R. C., Stampley, J., Davis, G., Li, Z., Cho, E., Kim, Y., Doiron, J. E., Spielmann, G., Ghosh, S. K., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.07.009 · Cited by 26
Self-citationIncretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
Diamond, C., Pansini, M., Hamid, A., Eichert, N., Pandya, P., Ali, S. N., Kemp, G. J., Thanabalasingham, G., Thomaides-Brears, H. B., & Cuthbertson, D. J. (2024) · Diabetes · doi:10.2337/db23-0926 · Cited by 27
What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 37
Taylor, E. B., Hall, J. E., & Mouton, A. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107761 · Cited by 29
“In the recent STEP-HF and SUMMIT clinical trials, once-weekly semaglutide or tirzepatide improved primary outcomes in HFpEF patients after 52 weeks, such as exercise performance and reduced hospitalization [169,170].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 24
“45 Similarly, previous studies showed that caloric restriction with or without aerobic training improved peak VO 2 in obese elderly HFpEF patients.”
BackgroundMethodResultInfluentialNet prices of new antiobesity medications
Hernandez, I., & Sullivan, S. D. (2024) · Obesity · doi:10.1002/oby.23973 · Cited by 22
“…a 20% reduction in the risk of major cardiovascular events in adults with overweight or obesity and a history of myocardial infarction, stroke, or peripheral arterial disease of the extremities and an improvement in heart failure-related symptoms in patients with obesity and heart failure [3, 17].”
BackgroundRashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 25
Self-citationSiddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 24
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23
Irving, C. A., Azeka, E., Adorisio, R., Blume, E. D., Bogle, C., Chubb, H., Conway, J. L., Cousino, M. K., Edelson, J. B., Ford, K., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.06.003 · Cited by 33
Mahmood, A., Dhall, E., Primus, C., Gallagher, A. M., Zakeri, R., Mohammed, S. F., Chahal, C. A. A., Ricci, F., Aung, N., & Khanji, M. Y. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae053 · Cited by 30
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 27
“…trial demonstrated that in patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss compared to the placebo [65].”
BackgroundInfluentialWhy are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
“19,20 These improvements are likely in part attributable to enhanced muscle quality, re fl ected in both strength and function, potentially due to increased insulin sensitivity and reduced ectopic fat deposition.”
Marques, P. S., Travlos, C. K., Matias, P., Neves, J. S., Tsoukas, M. A., Mavrakanas, T. A., Joza, J. E., Ferreira, J. P., & Sharma, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102573 · Cited by 22
Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 27
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
Review of Exercise Interventions to Improve Clinical Outcomes in Nondialysis CKD
Hayden, C., Begue, G., Gamboa, J. L., Baar, K., & Roshanravan, B. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.07.032 · Cited by 23
“210 Given the high prevalence of diastolic heart failure and obesity in patients with CKD these treatments appear promising.”
Advances in body composition: a 100-year journey
Heymsfield, S. B. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01511-9 · Cited by 26
“These observations were recently ampli fi ed when Kosiborod et al. [26] showed that reductions in adiposity following administration of a glucagon-like peptide-1 receptor agonist signi fi cantly improved multiple physical functions in patients with obesity and HFpEF.”
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“The STEP-HFpEF trial further demonstrated semaglutide’s benefits on functional symptoms and physical limitations in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) [95].”
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women
Qin, H., Tromp, J., ter Maaten, J. M., Voordes, G. H. D., van Essen, B. J., de la Rambelje, M. A., van der Hoef, C. C. S., Santema, B. T., Lam, C. S. P., & Voors, A. A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.022 · Cited by 27
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
Finan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“GLP-1R agonism is a highly effective treatment of T2D and obesity, including additional bene fi ts beyond glycemic control and chronic weight management, such as reduced cardiovascular complications [31 e 33].”
Intentional Weight Loss in Overweight and Obese Patients with Heart Failure: A Systematic Review
Peck, K. H., Dulay, M. S., Hameed, S., Rosano, G., Tan, T., & Dar, O. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3270 · Cited by 22
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
Self-citationRADAKRISHNAN, A., AGRAWAL, S., SINGH, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.008 · Cited by 23
Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure
Klein, K. R., Lingvay, I., Tuttle, K. R., & Flythe, J. E. (2024) · Diabetes Care · doi:10.2337/dci24-0081 · Cited by 27
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
Wallner, M., Biber, M. E., Stolfo, D., Sinagra, G., Benson, L., Dahlström, U., Guðbjörnsdóttir, S., Cosentino, F., Mol, P. G. M., Rosano, G. M. C., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae026 · Cited by 25
Self-citationGlucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Gaw, C. E., Hays, H. L., Kemp, C. A., Kistamgari, S., Spiller, H. A., Rine, N. I., Rhodes, A. L., Zhu, M., & Smith, G. A. (2024) · Journal of Medical Toxicology · doi:10.1007/s13181-024-00999-x · Cited by 20
Reddy, Y. N. V., Noseworthy, P. A., Borlaug, B. A., & Albert, N. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.010 · Cited by 23
Self-citationLala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 27
“While formal recommendations have not been incorporated into guidelines with respect to use of incretin-based therapies specifically for HF prevention among patients with obesity but without T2DM, accumulating evidence support incorporation in future guideline iterations [82 – 85].”
Atrial Shunt Therapy for Heart Failure: An Update
Jagadeesan, V. S., Gray, W. A., & Shah, S. J. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101203 · Cited by 25
“15 Despite these signi fi cant advancements in the treatment of HF across the range of EF, morbidity and mortality remain high.”
BackgroundSelf-citation
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.